Rodman & Renshaw Downgrades ABIOMED (ABMD) to Market Underperform, Sets $13 Price Target
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Rodman & Renshaw downgraded shares of ABIOMED (NASDAQ: ABMD) to a Market Underperform rating from its previous rating of Market Perform. The firm also set a new price target of $13.
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $18.25 yesterday.
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $18.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
- Berenberg Downgrades Inter Parfums (IPAR) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Rodman & RenshawSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
